BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Prasinezumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Prasinezumab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07174310-1655@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Prasinezumab: Phase 3 readout est. (NCT07174310)
DESCRIPTION:Prasinezumab\, phase 3\, Parkinson's Disease.\nStudy: A Study t
 o Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Par
 ticipants With Early-Stage Parkinson's Disease\nEstimated primary completi
 on: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pra
 sinezumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07174310
URL:https://assetmemo.bio/drug/prasinezumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07055087-1655@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Prasinezumab: Phase 2 readout est. (NCT07055087)
DESCRIPTION:Prasinezumab\, phase 2\, Parkinson's Disease.\nStudy: Prevent C
 ognitive Decline in GBA-associated Parkinson's Disease\nEstimated primary 
 completion: December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/prasinezumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07055087
URL:https://assetmemo.bio/drug/prasinezumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
